Cargando…
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients will benefit from immune checkpoint therapy and use of these medications carry serious autoimmune adverse effects. Therefore, biomarkers are needed to better identify patients who will benefit from its use. Here, the correlation of over...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413036/ https://www.ncbi.nlm.nih.gov/pubmed/37577328 http://dx.doi.org/10.21037/tlcr-23-7 |
_version_ | 1785087047391772672 |
---|---|
author | Sung, MinDong Jang, Won Seok Kim, Hae Reong Park, Ji Ae Lim, Sun Min Kim, Hye Ryun Cho, Byoung Chul Park, Yu Rang Hong, Min Hee |
author_facet | Sung, MinDong Jang, Won Seok Kim, Hae Reong Park, Ji Ae Lim, Sun Min Kim, Hye Ryun Cho, Byoung Chul Park, Yu Rang Hong, Min Hee |
author_sort | Sung, MinDong |
collection | PubMed |
description | BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients will benefit from immune checkpoint therapy and use of these medications carry serious autoimmune adverse effects. Therefore, biomarkers are needed to better identify patients who will benefit from its use. Here, the correlation of overall survival (OS) with baseline and early treatment period serum biomarker responses was evaluated in patients with NSCLC undergoing immunotherapy. METHODS: Patients diagnosed with NSCLC undergoing immunotherapy (n=597) at a tertiary academic medical center in South Korea were identified between January 2010 and November 2021. The neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP), and lactate dehydrogenase (LDH) levels in the survival and non-survival groups were examined at baseline and early treatment periods. Additionally, aberrant laboratory parameters at each period were used to stratify survival curves and examine their correlation with one-year OS. RESULTS: In the non-survival group, the NLR, CRP, and LDH levels at the early treatment period were higher than those at the baseline (P<0.001). The survival curves stratified based on aberrant laboratory findings in each period varied (log-rank test P<0.001). Multivariate Cox regression analysis revealed that having prescribed more than 3rd line of chemotherapy [hazard ratio (HR) =3.19, 95% confidence interval (CI): 1.04–9.82; P=0.043] and early treatment period CRP (HR =3.88; 95% CI: 1.55–9.72; P=0.004) and LDH (HR =4.04; 95% CI: 2.01–8.12; P<0.001) levels were significant predictors of one-year OS. CONCLUSIONS: Early treatment period CRP and LDH levels were significant predictors of OS in patients with NSCLC undergoing immunotherapy. |
format | Online Article Text |
id | pubmed-10413036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-104130362023-08-11 Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy Sung, MinDong Jang, Won Seok Kim, Hae Reong Park, Ji Ae Lim, Sun Min Kim, Hye Ryun Cho, Byoung Chul Park, Yu Rang Hong, Min Hee Transl Lung Cancer Res Original Article BACKGROUND: Not all non-small cell lung cancer (NSCLC) patients will benefit from immune checkpoint therapy and use of these medications carry serious autoimmune adverse effects. Therefore, biomarkers are needed to better identify patients who will benefit from its use. Here, the correlation of overall survival (OS) with baseline and early treatment period serum biomarker responses was evaluated in patients with NSCLC undergoing immunotherapy. METHODS: Patients diagnosed with NSCLC undergoing immunotherapy (n=597) at a tertiary academic medical center in South Korea were identified between January 2010 and November 2021. The neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP), and lactate dehydrogenase (LDH) levels in the survival and non-survival groups were examined at baseline and early treatment periods. Additionally, aberrant laboratory parameters at each period were used to stratify survival curves and examine their correlation with one-year OS. RESULTS: In the non-survival group, the NLR, CRP, and LDH levels at the early treatment period were higher than those at the baseline (P<0.001). The survival curves stratified based on aberrant laboratory findings in each period varied (log-rank test P<0.001). Multivariate Cox regression analysis revealed that having prescribed more than 3rd line of chemotherapy [hazard ratio (HR) =3.19, 95% confidence interval (CI): 1.04–9.82; P=0.043] and early treatment period CRP (HR =3.88; 95% CI: 1.55–9.72; P=0.004) and LDH (HR =4.04; 95% CI: 2.01–8.12; P<0.001) levels were significant predictors of one-year OS. CONCLUSIONS: Early treatment period CRP and LDH levels were significant predictors of OS in patients with NSCLC undergoing immunotherapy. AME Publishing Company 2023-07-14 2023-07-31 /pmc/articles/PMC10413036/ /pubmed/37577328 http://dx.doi.org/10.21037/tlcr-23-7 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Sung, MinDong Jang, Won Seok Kim, Hae Reong Park, Ji Ae Lim, Sun Min Kim, Hye Ryun Cho, Byoung Chul Park, Yu Rang Hong, Min Hee Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title_full | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title_fullStr | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title_full_unstemmed | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title_short | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
title_sort | prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, c-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413036/ https://www.ncbi.nlm.nih.gov/pubmed/37577328 http://dx.doi.org/10.21037/tlcr-23-7 |
work_keys_str_mv | AT sungmindong prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT jangwonseok prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT kimhaereong prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT parkjiae prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT limsunmin prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT kimhyeryun prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT chobyoungchul prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT parkyurang prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy AT hongminhee prognosticvalueofbaselineandearlytreatmentresponseofneutrophillymphocyteratiocreactiveproteinandlactatedehydrogenaseinnonsmallcelllungcancerpatientsundergoingimmunotherapy |